المؤلفون: Blok, E.J., Kroep, J.R., Kranenbarg, E.M.K., Duijm-de Carpentier, M., Putter, H., Liefers, G.J., Nortier, J.W.R., Rutgers, E.J.T., Seynaeve, C.M., Velde, C.J.H. van de, IDEAL Study Grp

المساهمون: Medical Oncology

المصدر: Breast Cancer Research and Treatment
Breast Cancer Research and Treatment, 168(2), 413-420. Springer New York
Breast Cancer Research and Treatment, 168(2), 413-420

مصطلحات موضوعية: 0301 basic medicine, Oncology, Cancer Research, medicine.medical_specialty, Time Factors, Antineoplastic Agents, Hormonal, Breast Neoplasms, Kaplan-Meier Estimate, Disease-Free Survival, 03 medical and health sciences, 0302 clinical medicine, Breast cancer, SDG 3 - Good Health and Well-being, Internal medicine, medicine, Adjuvant therapy, Humans, Adjuvant, IDEAL, Aged, Netherlands, Extended, business.industry, Proportional hazards model, Aromatase Inhibitors, Letrozole, Middle Aged, medicine.disease, Clinical Trial, Subgroup, Postmenopause, 030104 developmental biology, Prior Therapy, Receptors, Estrogen, Chemotherapy, Adjuvant, 030220 oncology & carcinogenesis, Lymphatic Metastasis, Cohort, Postmenopausal, Female, business, Tamoxifen, Hormone, medicine.drug, Follow-Up Studies

وصف الملف: application/pdf

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b93f1bbf320c154e35572f3628604c7aTest
http://europepmc.org/articles/PMC5838141Test

المؤلفون: Blok, E.J., Kroep, J.R., Kranenbarg, E.M.K., Duijm-De Carpentier, M., Putter, H., Liefers, G.J., Nortier, J.W.R., Rutgers, E.J.T., Seynaeve, C.M., Velde, C.J.H. van de, IDEAL Study Group, TEAM Study Group

المساهمون: Medical Oncology

المصدر: European Journal of Cancer, 95, 59-67
European Journal of Cancer, 95, 59-67. Elsevier Ltd.

مصطلحات موضوعية: Oncology, Cancer Research, Time Factors, Survival, chemistry.chemical_compound, 0302 clinical medicine, Breast cancer, Exemestane, Medicine, 030212 general & internal medicine, education.field_of_study, Aromatase Inhibitors, Letrozole, Hazard ratio, Middle Aged, Extended endocrine therapy, Postmenopause, Clinical trial, Treatment Outcome, Chemotherapy, Adjuvant, 030220 oncology & carcinogenesis, Female, medicine.drug, Compliance, medicine.medical_specialty, Antineoplastic Agents, Hormonal, Decision Making, Population, Breast Neoplasms, Drug Administration Schedule, 03 medical and health sciences, SDG 3 - Good Health and Well-being, Internal medicine, Adjuvant therapy, Humans, education, Aged, Neoplasm Staging, business.industry, Early treatment discontinuation, Aromatase inhibitor, medicine.disease, Discontinuation, Tamoxifen, chemistry, Adverse events, business

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d486b65ea2eb3d71c07edc8efa8a0b64Test
https://hdl.handle.net/1887/95506Test